Brief: Vivoryon Therapeutics Says VIVIAD Phase 2B Study Does Not Meet Primary Endpoints
04/03/2024 17:55
March 4 (Reuters) - Vivoryon Therapeutics NV 05Y.F :
* VIVORYON THERAPEUTICS N.V. PROVIDES UPDATE ON VIVIAD PHASE
2B
STUDY OF VAROGLUTAMSTAT IN EARLY ALZHEIMER’S DISEASE
* VIVIAD PHASE 2B STUDY DID NOT MEET ITS PRIMARY AND KEY
SECONDARY
ENDPOINTS
* FURTHER UPDATE EXPECTED TO BE PROVIDED NO LATER THAN WITH
PUBLICATION OF FY 2023 FINANCIAL RESULTS
Source text for Eikon: ID:nGNE2qdTJz
Further company coverage: 05Y.F
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587785110;))
Recent news on Vivoryon Therapeutics NV
See all newsEurope Research Roundup: Colonial, Covivio SA, Fluidra SA
Brief: Vivoryon Therapeutics Says VIVIAD Phase 2B Study Does Not Meet Primary Endpoints
Brief: Vivoryon Reports Positive Outcome To Proceed With Alzheimer Drug Study
Jefferies starts Vivoryon at 'buy' on positive risk/reward from Alzheimer's pill
Brief: Vivoryon Therapeutics Announces Proposed Appointment Of Frank Weber As Chief Executive Officer